Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease (NAFLD) in smokers. In addition to the lung and the brain, nicotine can accumulate in the intestine, where the bacteria Bacteroides xylanisolvens could reduce its concentration and the severity of NAFLD. In their study, published in Nature Oct. 19, 2022, the researchers described the enzymes involved in this process and a new undiscovered pathway.
Researchers based at the City University of New York (CUNY) have designed a deep learning artificial intelligence (AI) model that can improve preclinical predictions of drug responses in humans. As outlined in the Oct. 17, 2022, online issue of Nature Machine Intelligence, the researchers believe their model – a context-aware deconfounding autoencoder (CODE-AE) – can help improve the quality of early drug response prediction and help reduce subsequent clinical trial failures.
At the recent European Association of Nuclear Medicine meeting in Barcelona, researchers from the British Columbia Cancer Research Institute and the University of British Columbia reported the development and preclinical evaluation of bispecific radiotracers designed to target prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP).
China's National Medical Products Administration (NMPA) has cleared an IND application for a clinical trial of Shanghai Henlius Biotech Inc.'s HLX-60 for the treatment of solid tumors and lymphomas.
Hpvac SA has announced new data on its lead compound Hpvac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.
Zymeworks Inc. has described new antibody-drug conjugates (ADCs) consisting of a cysteine engineered full-length antibody (IgG type) targeting hepatocyte growth factor receptor (HGFR; MET) or folate receptor α (FOLR1; FR- α) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.